Cencora, Inc. (NYSE:COR) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA decreased its position in Cencora, Inc. (NYSE:COR - Free Report) by 0.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 938,478 shares of the company's stock after selling 2,503 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.48% of Cencora worth $260,981,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in COR. Asahi Life Asset Management CO. LTD. bought a new stake in Cencora during the 1st quarter worth about $431,000. Apollon Wealth Management LLC boosted its position in shares of Cencora by 11.1% during the first quarter. Apollon Wealth Management LLC now owns 5,949 shares of the company's stock worth $1,654,000 after buying an additional 596 shares during the period. Signaturefd LLC grew its position in Cencora by 3.9% in the first quarter. Signaturefd LLC now owns 3,755 shares of the company's stock valued at $1,044,000 after purchasing an additional 141 shares in the last quarter. CWM LLC increased its position in shares of Cencora by 0.9% during the 1st quarter. CWM LLC now owns 10,217 shares of the company's stock worth $2,841,000 after purchasing an additional 95 shares during the last quarter. Finally, TFR Capital LLC. acquired a new position in shares of Cencora during the 1st quarter worth approximately $1,590,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on COR. Jefferies Financial Group raised their target price on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. UBS Group lifted their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Citigroup raised their price target on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an "equal weight" rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $309.83.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,127 shares of company stock worth $9,812,296 over the last 90 days. Insiders own 10.80% of the company's stock.

Cencora Stock Up 1.1%

NYSE COR traded up $3.18 during midday trading on Wednesday, hitting $297.83. 1,323,704 shares of the company traded hands, compared to its average volume of 1,505,926. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The company has a market cap of $57.73 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The company's 50-day simple moving average is $291.96 and its 200-day simple moving average is $271.13.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.80 earnings per share. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.74%. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.